相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle et al.
Lancet Gastroenterology & Hepatology (2021)
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2020)
Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair
Jianhui Ma et al.
CANCER CELL (2019)
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
Philip Jonsson et al.
CLINICAL CANCER RESEARCH (2019)
Genetic and molecular epidemiology of adult diffuse glioma
Annette M. Molinaro et al.
NATURE REVIEWS NEUROLOGY (2019)
Fibroblast Growth Factor Receptor Functions in Glioblastoma
Ana Jimenez-Pascual et al.
CELLS (2019)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2019)
Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis
Elena V. Daoud et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
Sumanta K. Pal et al.
CANCER DISCOVERY (2018)
Insights From Molecular Profiling of Adult Glioma
Phedias Diamandis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Effect of Molecular Diagnostics on the Treatment of Glioma
Nancy Ann Oberheim Bush et al.
CURRENT ONCOLOGY REPORTS (2017)
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
Rouzbeh Banan et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma
Anna Luisa Di Stefano et al.
CLINICAL CANCER RESEARCH (2015)
Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4
Jyothsna Gattineni et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Vito Guagnano et al.
CANCER DISCOVERY (2012)
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Vito Guagnano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
V Rand et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy:: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
AA Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
